Cardiotoxicity is one of the leading causes of drug attrition during development, and accounts for 22-28% of US post-marketing drug withdrawal. Therefore, developing sensitive in vitro assays assessing drug-induced cardiotoxicity in preclinical and early clinical stages is especially important for drug development.

The TargetMol’s Cardiotoxicity Compound Library, a unique collection of 131 cardiotoxicity inducing compounds, can be used for chemical toxicity evaluation and prediction.